Epigenetic Plasticity in Lung Cancer Therapy Resistance: Mechanisms, Biomarkers, and Rational Combination Strategies
Year: 2026
Type: article
Abstract: Lung cancer resistance is commonly attributed to acquired genetic alterations, including on-target mutations, activation of bypass pathways, tumor-suppressor loss, and histologic or lineage transformation. However, genetic evolution alone cannot fully account for the rapid, reversible, and heterogeneous adaptations that emerge during treatment. Epigenetic plasticity, mediated through DNA methylation, histone modifications, chromatin-remodeling complexes, and transcriptional state transitions, enables tumor cells to enter drug-tolerant states, alter lineage identity, evade immune surveillance, and persist under therapeutic pressure, creating conditions in which more stable forms of resistance can develop. This review examines how epigenetic programs interact with oncogenic drivers and tumor-suppressor loss to shape therapy resistance across lung cancer. We discuss chromatin-mediated resistance to targeted therapies, cytotoxic chemotherapy, and immune checkpoint blockade, with particular attention to drug-tolerant persister states, epithelial–mesenchymal and neuroendocrine transitions, impaired antigen presentation, and remodeling of the tumor microenvironment. We critically assess the evidence for DNA methyltransferase and histone deacetylase inhibitors, together with emerging strategies targeting EZH2/EZH1, LSD1, BET proteins, PRMT5/MAT2A, and vulnerabilities associated with SWI/SNF dysfunction. Clinical translation has been limited by modest single-agent activity, treatment-related toxicity, incomplete pharmacodynamic assessment, and inadequate biomarker-based patient selection. Future progress will depend on matching epigenetic interventions to defined biological states, confirming intratumoral target engagement, and integrating longitudinal multiomic profiling to guide patient selection, treatment sequencing, and early interception of emerging resistance.
Source: Genes
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: lung cancer, treatment resistance, epigenetic plasticity, DNA methylation, histone modifications, chromatin remodeling, epithelial-mesenchymal transition, neuroendocrine differentiation, immune checkpoint inhibitor resistance, chemoresistance, targeted therapy resistance, hypomethylating agents, histone deacetylase inhibitors, EZH2, LSD1, BET proteins, tumor microenvironment, biomarkers, combination therapy
Open Access status: gold
Estimated APC paid: $3,137
OpenAlex ID: W7233861519
